Literature DB >> 26974751

The Etiology, Clinical Presentation and Long-term Outcome of Spondylodiscitis in Children.

Hyun Mi Kang1, Eun Hwa Choi, Hoan Jong Lee, Ki Wook Yun, Choon-Ki Lee, Tae-Joon Cho, Jung-Eun Cheon, Hyunju Lee.   

Abstract

BACKGROUND: Spondylodiscitis (SD) is a rare disease in children and diagnosis can be delayed because of the scarcity in incidence and lack of awareness. The purpose of this study was to evaluate and report the microbiologic epidemiology and clinical features of pediatric SD in South Korea.
METHODS: This was a retrospective study of children <19 years old admitted for the treatment of SD between 2000 and 2014. Electronic medical records were reviewed for clinical parameters and etiologic agents.
RESULTS: During the 15-year period, 25 patients were diagnosed with SD. The median age was 13.8 years, and 60% were male. Back pain was the most common presenting symptom (n = 17; 68%), and only 52% (n = 13) of the patients had a history of fever (≥38.0°C). In patients younger than 3 years, irritability (n = 5; 62.5%) was the most predominant symptom. Microorganisms were isolated in 22 cases, the most common being Staphylococcus aureus (40%) and Mycobacterium tuberculosis (32%). Of the 25 patients, 64% (n = 16) had blood cultures taken, 56% (n = 14) underwent percutaneous fluoroscopy-guided biopsy, and 48% (n = 12) underwent open surgical biopsy. The positive rate for microbiologic diagnosis of each method was 18.8% (n = 3) for blood culture, 71.4% (n = 10) for percutaneous biopsy and 100% (n = 12) for surgical biopsy. Overall, 52% (n = 13) needed surgical treatment along with antibiotic therapy. Patients who needed surgery had a significant delay in diagnosis compared with those that did not (median, 60 vs. 31 days; P = 0.014).
CONCLUSIONS: S. aureus and M. tuberculosis are the predominant causes of SD in children in South Korea. Obtaining tissue culture is important to confirm the bacterial etiology of the infection and appropriately guide antibiotic therapy in a community in which the endemic organisms require treatment pathways that are widely divergent.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26974751     DOI: 10.1097/INF.0000000000001043

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Paediatric spondylodiscitis: a 10-year single institution experience in management and clinical outcomes.

Authors:  Fardad T Afshari; Desiderio Rodrigues; Mahesh Bhat; Guirish A Solanki; A Richard Walsh; William B Lo
Journal:  Childs Nerv Syst       Date:  2019-12-17       Impact factor: 1.475

2.  Delayed diagnosis of osteodiscitis in an adolescent athlete: a case report.

Authors:  Dominique Harmath; Erin Boynton; Peter Lejkowski
Journal:  J Can Chiropr Assoc       Date:  2021-12

3.  Spondylodiscitis in Paediatric Patients: The Importance of Early Diagnosis and Prolonged Therapy.

Authors:  Sonia Bianchini; Andrea Esposito; Nicola Principi; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2018-06-07       Impact factor: 3.390

Review 4.  Characteristics, Management and Outcomes of Spondylodiscitis in Children: A Systematic Review.

Authors:  Irene Ferri; Gabriele Ristori; Catiuscia Lisi; Luisa Galli; Elena Chiappini
Journal:  Antibiotics (Basel)       Date:  2020-12-31

5.  Spondylodiscitis complicated by paraspinal abscess in a 10-year-old child.

Authors:  Maria Francesca Gicchino; Nicoletta di Maio; Anna Di Sessa
Journal:  Rev Soc Bras Med Trop       Date:  2021-04-28       Impact factor: 1.581

6.  What Do We Know about Spondylodiscitis in Children? A Retrospective Study.

Authors:  Ayla Yagdiran; Charlotte Meyer-Schwickerath; Raphael Wolpers; Christina Otto-Lambertz; Katrin Mehler; Andre Oberthür; Nikolaus Kernich; Peer Eysel; Norma Jung; Kourosh Zarghooni
Journal:  Children (Basel)       Date:  2022-07-22

Review 7.  Infectious Discitis and Spondylodiscitis in Children.

Authors:  Nicola Principi; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2016-04-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.